MediPharm Labs (TSE:LABS)
TSX:LABS
Want to see TSE:LABS full AI Analyst Report?
LABS Stock Chart & Stats
C$0.08
<C$0.01(7.69%)
At close: 4:00 PM EST
C$0.08
<C$0.01(7.69%)
Day’s Range― - ―
52-Week RangeC$0.06 - C$0.10
Previous CloseN/A
Volume690.59K
Average Volume (3M)466.64K
Market Cap
C$33.99M
Enterprise ValueC$22.02M
Total Cash (Recent Filing)C$9.87M
Total Debt (Recent Filing)C$18.00K
Price to Earnings (P/E)―
Beta0.91
Next Earnings
Aug 17, 2026EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding424,864,260
10 Day Avg. Volume458,518
30 Day Avg. Volume466,636
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)0.76
Price to Sales (P/S)0.61
P/FCF Ratio-4.88
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)C$38.98M
Bulls Say, Bears Say
Bulls Say
Very Low Leverage / Strong Balance SheetExtremely low leverage and a sizable equity base materially reduce refinancing and interest-rate risk, providing structural resilience while the business repairs operating performance. This balance-sheet optionality supports working capital, selective M&A or investment without immediate external funding.
High, Durable Gross MarginsSustained ~37% gross margins reflect favorable product mix and premium international sales, creating a lasting cushion to absorb revenue volatility. High gross margins improve the path to operating profitability as cost structure tightens, enabling margin-driven recovery rather than volume dependence.
Regulated International Traction & Pharma CredentialsDiversified, regulated international revenue reduces reliance on domestic markets and seasonal cycles. Combined with FDA/Health Canada/EU GMP credentials, the company gains durable commercial optionality into pharma/API supply and clinical R&D, expanding addressable markets beyond volatile adult‑use retail.
Bears Say
Negative Operating And Free Cash FlowPersistent negative operating and free cash flow means the business is consuming cash to fund operations. Over a multi‑month horizon this pressures liquidity and limits reinvestment in growth or capacity. Absent sustained profitable cash generation, management may need dilutive financing or asset sales.
Ongoing Net Losses And Negative ROEDespite margin improvement at gross level, persistent operating and net losses produce negative returns on equity, indicating the capital base is not being productively employed. Structural inability to convert margins into positive ROE risks capital dilution and undermines long‑term shareholder value creation.
Top‑line Pressure And Reimbursement HeadwindsMeaningful YoY revenue decline alongside payer reimbursement cuts and contraction in adult‑use demand reduce volume and pricing power over coming months. These structural market and regulatory headwinds can delay recovery of scale economics and compress margins even as cost reductions proceed.
MediPharm Labs News
LABS FAQ
What was MediPharm Labs’s price range in the past 12 months?
MediPharm Labs lowest stock price was C$0.06 and its highest was C$0.10 in the past 12 months.
What is MediPharm Labs’s market cap?
MediPharm Labs’s market cap is C$33.99M.
When is MediPharm Labs’s upcoming earnings report date?
MediPharm Labs’s upcoming earnings report date is Aug 17, 2026 which is in 74 days.
How were MediPharm Labs’s earnings last quarter?
MediPharm Labs released its earnings results on May 13, 2026. The company reported C$0 earnings per share for the quarter, beating the consensus estimate of -C$0.003 by C$0.003.
Is MediPharm Labs overvalued?
According to Wall Street analysts MediPharm Labs’s price is currently Overvalued.
Does MediPharm Labs pay dividends?
MediPharm Labs does not currently pay dividends.
What is MediPharm Labs’s EPS estimate?
MediPharm Labs’s EPS estimate is >-0.01.
How many shares outstanding does MediPharm Labs have?
MediPharm Labs has 424,864,260 shares outstanding.
What happened to MediPharm Labs’s price movement after its last earnings report?
MediPharm Labs reported an EPS of C$0 in its last earnings report, beating expectations of -C$0.003. Following the earnings report the stock price went up 12.5%.
Which hedge fund is a major shareholder of MediPharm Labs?
Currently, no hedge funds are holding shares in TSE:LABS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
MediPharm Labs
MediPharm Labs Corp., a pharmaceutical company, produces and sells pharmaceutical-quality cannabis oil and concentrates, and advanced derivative products in Canada, Australia, Germany, and internationally. It formulates, processes, packages, and distributes cannabis extracts and advanced cannabinoid-based products. The company also provides GMP flower sourcing, packaging, and distribution services. MediPharm Labs Corp. was founded in 2015 and is headquartered in Barrie, Canada.
LABS Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call balanced clear near-term challenges—most notably a ~16.7% YoY revenue decline, a widened net loss and industry reimbursement headwinds—with several material positives: return to positive adjusted EBITDA, a strong 37% gross margin, meaningful operating expense reductions (‑14% YoY, ‑28% sequential), $1.0M in expected annualized savings, $9.9M cash and limited debt, and continued international commercial traction (France, New Zealand, Brazil, Germany). Management emphasizes disciplined, margin-focused execution and long-term pharma optionality supported by rare regulatory credentials. Given the company's demonstrated ability to protect margins, improve profitability metrics and maintain liquidity while advancing international expansion, the tone is cautiously optimistic.View all TSE:LABS earnings summariesTechnical Analysis
Options Prices
Currently, No data available
---